What's in Otsuka Holdings Co., Ltd.'s pipeline?

Otsuka Holdings Co., Ltd. has 5 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Otsuka Holdings Co., Ltd.'s portfolio?

Top competitors by shared drug class: , Alkermes Inc, Hisamitsu, Cheplapharm, Eli Lilly.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/otsuka.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Otsuka Holdings Co., Ltd. — Portfolio Competitive Intelligence Brief

Otsuka Holdings Co., Ltd. (OTSKY) pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

OTSKY (OTC) 5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Inqovi	Inqovi	marketed	Nucleoside Metabolic Inhibitor [EPC]	Cytidine deaminase	Oncology	2020-01-01
Rexulti	BREXPIPRAZOLE	marketed	Atypical Antipsychotic [EPC]	D(2) dopamine receptor	Neuroscience	2015-01-01
Samsca	TOLVAPTAN	marketed	Vasopressin V2 Receptor Antagonist [EPC]	Vasopressin V2 receptor	Metabolic	2009-01-01
Pletal	CILOSTAZOL	marketed	Phosphodiesterase 3 Inhibitor [EPC]	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Metabolic	1999-01-01
Tomefloxacin	GREPAFLOXACIN	marketed	grepafloxacin	Potassium voltage-gated channel subfamily H member 2	Infectious Disease	1997-01-01

Therapeutic area mix

Metabolic · 2
Infectious Disease · 1
Neuroscience · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2028-10-16 — Inqovi · 8618075 · US
2028-10-16 — Inqovi · 9567363 · US
2030-08-22 — Inqovi · 8268800 · US

Competitive overlap (companies sharing drug classes)

· 2 shared drug classes
Alkermes Inc · 1 shared drug class
Hisamitsu · 1 shared drug class
Cheplapharm · 1 shared drug class
Eli Lilly · 1 shared drug class
Extrovis · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Otsuka Holdings Co., Ltd.:

Cite this brief

Drug Landscape (2026). Otsuka Holdings Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/otsuka. Accessed 2026-05-13.